دورية أكاديمية
An update on the safety of lanreotide autogel for the treatment of patients with neuroendocrine tumors.
| العنوان: | An update on the safety of lanreotide autogel for the treatment of patients with neuroendocrine tumors. |
|---|---|
| المؤلفون: | Sood A; Department of Medicine, The Wright Center for Graduate Medical Education, Scranton, PA, USA., Munir M; Faculty of Medicine, Ain Shams University, Cairo, Egypt., Syed O; Department of Medicine, The Wright Center for Graduate Medical Education, Scranton, PA, USA., Mehta V; Department of Medicine, Mercy Catholic Medical Center, Darby, PA, USA., Kaur R; Department of Medicine, The Wright Center for Graduate Medical Education, Scranton, PA, USA., Kumar A; Department of Medicine, The Wright Center for Graduate Medical Education, Scranton, PA, USA., Sridhar A; Department of Medicine, The Wright Center for Graduate Medical Education, Scranton, PA, USA., Sood A; Department of Medicine, Navjivan General and Maternity Hospital, Jalandhar, Punjab, India., Gupta R; Lehigh Valley Heart Institute, Lehigh Valley Health Network, Allentown, PA, USA. |
| المصدر: | Expert opinion on drug safety [Expert Opin Drug Saf] 2024 Aug; Vol. 23 (8), pp. 949-957. Date of Electronic Publication: 2024 Jun 10. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101163027 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-764X (Electronic) Linking ISSN: 14740338 NLM ISO Abbreviation: Expert Opin Drug Saf Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2015- : Abingdon, Oxford : Taylor & Francis Original Publication: London : Ashley Publications, c2002- |
| مواضيع طبية MeSH: | Somatostatin*/analogs & derivatives , Somatostatin*/administration & dosage , Somatostatin*/adverse effects , Peptides, Cyclic*/administration & dosage , Peptides, Cyclic*/adverse effects , Neuroendocrine Tumors*/drug therapy , Neuroendocrine Tumors*/pathology , Antineoplastic Agents*/administration & dosage , Antineoplastic Agents*/adverse effects , Antineoplastic Agents*/pharmacology, Humans ; Carcinoma, Neuroendocrine/drug therapy ; Carcinoma, Neuroendocrine/pathology ; Gels ; Disease Progression |
| مستخلص: | Introduction: Neuroendocrine neoplasms (NENs) are a rare group of tumors originating from neuroendocrine cells in various organs. They include neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs), which differ in biological behavior and prognosis. NETs are usually well-differentiated and slow-growing, while NECs are poorly differentiated and more aggressive. Management of NETs often involves somatostatin analogs like octreotide and lanreotide to control tumor growth and alleviate symptoms, especially in well-differentiated NETs. Lanreotide is used to control tumor growth, and both lanreotide and octreotide alleviate symptoms. Treatment approaches may vary depending on the specific type and grade of the neuroendocrine neoplasm. Areas Covered: This review provides an update on the safety of lanreotide autogel in treating patients with NETs, through a comprehensive review of clinical trials, post-marketing surveillance, real-world evidence, and its safety profile. Specific adverse events, side effects, and potential risks associated with lanreotide autogel are discussed, along with risk mitigation strategies and recommendations for patient monitoring. Expert Opinion: The findings highlight the overall safety of lanreotide autogel in managing NETs, focusing on its efficacy in controlling hormone secretion, tumor progression, and symptom management. New safety concerns and precautions are also addressed to help healthcare providers make informed decisions when prescribing lanreotide autogel. |
| فهرسة مساهمة: | Keywords: Lanreotide autogel; adverse events; drug safety; neuroendocrine tumors; patient monitoring; somatostatin analogues; therapeutic efficacy |
| المشرفين على المادة: | 0G3DE8943Y (lanreotide) 51110-01-1 (Somatostatin) 0 (Peptides, Cyclic) 0 (Antineoplastic Agents) 0 (Gels) |
| تواريخ الأحداث: | Date Created: 20240607 Date Completed: 20240716 Latest Revision: 20240716 |
| رمز التحديث: | 20240716 |
| DOI: | 10.1080/14740338.2024.2365823 |
| PMID: | 38847075 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher | تدمد: | 1744-764X |
|---|---|
| DOI: | 10.1080/14740338.2024.2365823 |